Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.95 1.90 2.00 1.95 1.925 1.95 8,971,479 15:40:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.1 -0.0 - 63

Sareum Share Discussion Threads

Showing 12076 to 12098 of 12525 messages
Chat Pages: Latest  489  488  487  486  485  484  483  482  481  480  479  478  Older
DateSubjectAuthorDiscuss
14/12/2020
16:11
HOLD FOR GOLD.
tez123
14/12/2020
13:07
Interesting to compare valuation with Evgen (EVG) at just £11m cap but in phase 2b/3 clinical trials for its ARDS/COVID-19 drug. So either this stock at £55m is well overvalued or EVG is dramatically undervalued. Don't worry though I strongly suspect it's the latter.
on target
14/12/2020
13:00
Good post Monster. I am ip to 3m shares now, looks interesting to say the least. Without ramping, re your comment on vaccine delivery at low temperatures, take a look at the interview today with CEO of N4P (N4Pharma) where I am also heavily invested. It feels as crazy as SAR given they appear close to commercialising...dyor of course!!
savvy investor
14/12/2020
12:01
Pointless trading this. Sell and youll end up buying higher. If you want to trade ive been doing it well with rolls Royce
spacedust
14/12/2020
11:51
I would predict this becoming impossible to do quick trading on small margins. Only a fool would think they could make a quick 10% and buyback their same holding. We have achieved the difficult 40%er - the big one is loaded and ready!
barkboo
14/12/2020
10:47
Completely agree, time to let the share price do the talking now.
tez123
14/12/2020
10:41
Evidence suggests the Pfizer vaccine must be a 2 phase injection, otherwise only 52% effective. Think about the complications to get this vaccine to across the world at the storage temperatures required. If you asked people if they would rather not have a vaccine but a treatment IF they got ill. 1st generation JAK inhibitors are failing in the race for a treatment, wrong target, not tyk2, and side effects which don't help the patient. Sareums TYK2 SDC1801 is right on the money, ideal scenario would be for us to have safety data already but that timescale can be shortened for this need. SDC1802, closely related to SDC1801 can go straight into sick cancer patients. MMs will try and load up here but the sentiment is again strong and at any moment Tim could name drop and it's goodbye pennies.
monstersound
14/12/2020
10:24
Right on cue, in comes justtrying1 with his deramping, and the share price goes up !!
curriedquaker
14/12/2020
10:11
Selll off for the dog
justtrying1
14/12/2020
09:51
Https://www.bbc.com/news/health-54832563
tez123
14/12/2020
09:42
It doesn't deserve 40 it deserves 400. Your not looking past your keyboard, they have the only tyk2 available to license, and it's peer reviewed research not other people's news. Already supported by UK grant, a licence for their proprietary drug is worth a billion headline deal, at least. But good luck with your sell and catching it again.
monstersound
14/12/2020
09:41
14.12.20 The researchers found that the sequences implicated relate to genes involved in inflammatory processes and the body's response to invading viruses. "For example, the TYK2 gene is associated with the inflammatory responses that are known to cause the 'cytokine storm' that is responsible for the death of younger patients who contract [this] condition," said clinical senior lecturer David Strain of the University of Exeter and the British Medical Association, who was not involved in the research. "The reason this is of interest is that there are treatments that can block (inhibit) the receptor to this (JAK receptor) and thus may present [a] therapeutic option going forward (particularly given that the individuals most likely to experience cytokine storm are lower down the priority list for vaccinations)." [...]
andrbea
14/12/2020
09:38
Proactive article Https://cutt.ly/nhSwf5e
andrbea
14/12/2020
09:36
Makes total sense to me.Company is essentially retweeting others news and hopes that their drug candidate might be a relevant treatment as a result.Does that deserve 40% increase in SP? No. So sell and buy later when some of the the hot air cools.
officerdigby
14/12/2020
09:09
Probably banking whatever profits they can salvage as profits been eroding away since 3p
spacedust
14/12/2020
08:48
I’m genuinely shocked that any holder would be thick enough to sell in to this early movement today? LMFAO.
norma_stitts
14/12/2020
08:27
At long last, some decent PR coming out of Sareum in the form of a RNS. I think they are slowly realising that they need to shout about all the good science they have. Onwards and upwards.
curriedquaker
14/12/2020
08:06
rns and up 21%
andrbea
13/12/2020
21:16
Looking forward to this week. Should fly out of the traps tomorrow!
norma_stitts
12/12/2020
09:42
For reference. Remdisivir(gilead) has sales of 3bn for treatment of c19 symptoms. Despite the world health organisation saying its innefective (reduces hospitalisation by 1 day). The virus is endemic. Need for treatments for decades. And grant funding for trials now available (project WARP)
mrsapeslaptop
12/12/2020
09:11
Another similar article... Coronavirus: UK scientists identify drugs that may help severe cases Ian Sample Science editor 16 hrs ago hTTps://www.msn.com/en-gb/health/medical/coronavirus-uk-scientists-identify-drugs-that-may-help-severe-cases/ar-BB1bQIyb?ocid=msedgntp
kwizza
12/12/2020
08:13
Reference to TYK2 gene and JAK in terms of severe COVID treatment hxxps://apple.news/ADQzPOjxzR0WnJRNfWjpD7A
sthelensrlfc
11/12/2020
22:23
TYK2 just referenced on BBC News at 10!
norma_stitts
Chat Pages: Latest  489  488  487  486  485  484  483  482  481  480  479  478  Older
ADVFN Advertorial
Your Recent History
LSE
SAR
Sareum
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210418 14:23:53